Sanofi has formed an alliance with US-based drug discovery company Revolution Medicines to develop and commercialise potential treatments for non-small lung cancer and other types of cancer involving certain mutations.
Sanofi plans to combine its cancer research and drug development expertise with Revolution Medicines’ oncology discoveries and preclinical development of a small molecule, SHP2 inhibitor candidate called RMC-4630.
First-in-human clinical trials of RMC-4630 are expected to commence over the coming months.
Sanofi oncology development head Joanne Lager said: “This agreement demonstrates our continued commitment to develop new therapies for patients living with cancer.
“We look forward to working with Revolution Medicines to advance investigational therapies that could provide a new way to treat patients with non-small cell lung cancer and other cancers that have specific types of genetic mutations.”
Under the terms of the partnership, the companies will jointly work on the development of SHP2 inhibitors.
SHP2 inhibitors are cellular enzymes in the protein tyrosine phosphatase family. Revolution Medicines has discovered that SHP2 can regulate a cell growth signalling pathway called RAS-MAP kinase pathway, which is hyperactive in human cancers. Therefore, the drug can reduce the tumorigenic effects of the cancers.
Revolution Medicines will continue to be responsible for research and early clinical development, and Sanofi will take over the SHP2 programme’s subsequent development activities.
Sanofi will make a $50m upfront payment to Revolution Medicines, and also cover research and development (R&D) costs associated with the joint programme.
In addition, Sanofi will get an exclusive worldwide licence to commercialise any approved SHP2 targeting candidates, while Revolution Medicines will have an option for co-promotion in the US.
The partners plan to sign a 50/50 profit and loss share arrangement for the US market.
REVOLUTION Medicines will obtain a tiered royalty on sales in other markets, along with potentially more than $500m in development and regulatory milestone-based payments.